Relapsed ALL remains a leading cause of mortality among all childhood malignancies in spite of risk-stratified combination therapy and improved supportive care 1 . The thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are key drugs in the backbone of ALL combination chemotherapy 2 ; both are prodrugs converted by the purine salvage pathway to cytotoxic thioguanine nucleotides, so alterations in purine homeostasis can affect the therapeutic efficacy of these drugs [3][4] [5] .
a r t i c l e s
Relapsed ALL remains a leading cause of mortality among all childhood malignancies in spite of risk-stratified combination therapy and improved supportive care 1 . The thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are key drugs in the backbone of ALL combination chemotherapy 2 ; both are prodrugs converted by the purine salvage pathway to cytotoxic thioguanine nucleotides, so alterations in purine homeostasis can affect the therapeutic efficacy of these drugs [3] [4] [5] .
To investigate how genetic lesions contribute to relapse in childhood ALL, we performed whole-exome sequencing of 16 matched diagnosisremission-relapse triad samples followed by targeted sequencing in two independent large B-ALL validation cohorts; we then identified recurrent relapse-specific mutations in PRPS1, which encodes the first rate-limiting and allosteric enzyme in the purine biosynthesis pathway. In normal cells, PRPS activity is kept low by end-product feedback inhibition of PRPS1 and low expression of feedback-insensitive PRPS2 (ref. 6) . By integrating clinical data with functional findings, we elucidated a drug resistance mechanism in which deregulated feedback modulation of purine biosynthesis reduces thiopurine prodrug activation and impairs therapeutic efficacy. These results provide a rationale for developing therapeutic strategies to overcome thiopurine resistance in the clinic.
RESULTS

Identification of relapse-specific mutations
We performed whole-exome sequencing of triad samples obtained at diagnosis, remission and relapse from 16 individuals at Shanghai Children's Medical Center (SCMC) (Supplementary Table 1) . We excluded one set of T-ALL samples (ALL-060) with excessive mutations (540 non-silent variants in 526 genes) because of the concern that the unrepresentative hypermutation was caused by DNA repair defects. The remaining 15 triad samples contained 373 non-silent variants in 356 genes, of which 27 single-nucleotide variants (SNVs) and four indels were identified as diagnosis specific, 199 SNVs and 18 indels were relapse specific, and 116 SNVs and 9 indels were shared between the diagnosis and relapse samples ( Supplementary Fig. 1 and Supplementary Tables 2 and 3). Changes from C/G to T/A were most frequent (52.5%; Supplementary Fig. 2) , as reported in a r t i c l e s 5 6 4 VOLUME 21 | NUMBER 6 | JUNE 2015 nature medicine recent ALL studies 7, 8 . Our genomic analysis identified 164 somatic copy number alterations (CNAs; 125 deletions and 39 amplifications) (Supplementary Tables 4 and 5), of which 46 were identified as diagnosis specific, 26 were relapse specific and 92 were shared (Supplementary Fig. 2 and Supplementary Table 6) . Notably, 9p21.3 was the most frequent site at which CNAs occurred, with ten deletions of CDKN2A or CDKN2B, which is consistent with previous reports 9 .
We observed somatic mutations known to be associated with ALL, including those in NRAS, KRAS, JAK1, PAX5, IKZF1, ARID1A, NOTCH1 and FBXW7, in both diagnostic and relapse samples. In the 15 triad samples, two genes, PRPS1 and C1orf173 (officially known as ERICH3), showed multiple relapse-specific mutations ( Supplementary  Fig. 3 ). Further sequencing in an independent Chinese cohort of 144 relapsed ALL cases and a German cohort of 220 relapsed B-ALL cases identified relapse-specific mutations in 24 individuals at 14 sites in PRPS1 ( Table 1 and Supplementary Table 7 ). All individuals in the Chinese cohort were enrolled in either the XH-ALL-99 (n = 56) or SCMC-ALL-2005 (n = 88) treatment protocols 10, 11 . More than 95% of the 220 German individuals had received front-line treatment according to either the German ALL-BFM (n = 154) or COALL protocol (n = 56) and all individuals had received relapse treatment according to the ALL-REZ BFM 2002 protocol [12] [13] [14] . After combining the data from the discovery and validation cohorts of Chinese and German individuals, we observed 17 distinct PRPS1 mutations affecting 14 evolutionarily conserved amino acid residues (Fig. 1a) . Among them, A190V was an activating mutation previously described in inherited gout 15 . The most common PRPS1 mutation we found was A190T at the same codon, present in 10 of the 24 individuals at relapse (Table 1) . We found no PRPS1 mutations in the Chinese T-ALL subcohort (n = 22), so we focused our PRPS1 study on B-ALL unless otherwise specified. We found no relapse-specific 5′-nucleotidase, cytosolic II gene (NT5C2) mutations 7, 8 in the Chinese B-ALL cohort (n = 45), whereas seven individuals in the German cohort (n = 115; 7/115, 6.1%) had NT5C2 mutations that were mutually exclusive with PRPS1 mutations 16 (Table 2) .
PRPS1 is a crucial purine biosynthesis component; therefore, we sequenced the genes ATIC (encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase), ADSL (encoding adenylosuccinate lyase), PPAT (encoding phosphoribosyl pyrophosphate amidotransferase), GART (encoding phosphoribosylglycinamide formyltransferase), PAICS (encoding phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase) and PFAS (encoding phosphoribosylformylglycinamidine synthase) in the de novo purine synthesis pathway; the thiopurine metabolism-related genes TPMT (encoding thiopurine S-methyltransferase) and NT5C2, and HPRT1 (encoding hypoxanthine-guanine phosphoribosyltransferase) from the Chinese validation cohort (n = 160). Sequencing and validation in 160 ALLmatched diagnosis-relapse bone marrow samples in the Chinese cohort (138 B-ALLs, 22 T-ALLs) revealed eight mutations in the de novo purine synthesis pathway in eight individuals aside from the PRPS1 mutations (Supplementary Table 8 ), implying the importance of the de novo purine synthesis pathway in relapse. Clinical and structural features of PRPS1 mutations The SCMC and BFM/COALL protocols for the treatment of childhood ALL use risk-adapted multi-agent chemotherapy, including maintenance therapy consisting of daily 6-MP or 6-TG and weekly methotrexate administration [10] [11] [12] [13] [14] . The overall frequency of PRPS1 mutations at relapse was 6.7% (24/358); it was higher in the Chinese cohort (13.0%, 18/138) than in the German cohort (2.7%, 6/220) ( Table 1) . Possible explanations for this include the observation that the Chinese cohort had more t(9;22) (BCR-ABL1 fusion gene)-positive individuals, fewer t(12;21) (TEL-AML1 fusion gene)-positive individuals and a higher percentage of on-treatment relapse (P < 0.001). Even though there were differences between therapeutic protocols and mutation frequencies, all 24 individuals with PRPS1 mutations experienced early relapse during treatment, within 36 months of initial diagnosis (Chinese cohort, P = 0.002; German cohort, P < 0.001) ( Table 2) .
To assess whether PRPS1 mutations were present at diagnosis as a rare subclone and could therefore have a causative role in relapse, we retraced four major PRPS1 mutations (including the two most frequent ones, A190T and N144S) by ultra-deep sequencing of serial bone marrow samples. Within the resolution of ultra-deep sequencing, none of these four individuals (ALL-011, ALL-141, ALL-005 and ALL-076) had PRPS1 mutations at diagnosis; furthermore, compared to previous time points, the proportion of mutated PRPS1 increased exponentially before clinical relapse, suggesting that drug-resistant clones with all these four major PRPS1 mutations (62.5%, 15/24 cases) could drive relapse (Fig. 1b) .
We mapped PRPS1 mutations to the reported crystal structure of human PRPS1 (refs. 17,18) to delineate their potential functional effects. Human PRPS1 exists as a hexamer comprising three homodimers 18, 19 ; among relapse-specific PRPS1 mutation sites, those encoding residues G174, K176, D183, A190 and L191 form part of the dimer interface and are positioned in proximity to allosteric site B, and those encoding residues N114 and D139 lie within the dimer interface but farther from the allosteric sites (Fig. 1c) . These mutations destabilize the dimer interface by disrupting favorable interactions, thus affecting the binding of GDP or ADP at allosteric site B, as previously described for activating mutants A190V and D183H (refs. 15,20) . S103 and N144 seem to function in GDP or ADP binding at allosteric sites A and B, whereas T303 is near allosteric site A (Fig. 1c) . These mutations can affect the binding of nucleotide inhibitors at the allosteric sites, as previously described for the activating mutants L129I and V142L (refs. 15,21) .
Relapse-specific PRPS1 mutations confer drug resistance On the basis of the role of PRPS1 in purine biosynthesis and the association of PRSP1 mutations with on-treatment relapse, we hypothesized that mutations in PRPS1 allow for resistance to nucleoside analogs during the maintenance phase of an ALL treatment protocol. We analyzed the effects of wild-type (WT) and mutant 2   V53A  l72V  C77S  S103T  S103N  S103I  N114D  N144S  D139G  G174E  L191F  A190V  T303S  Y311C  A190T  D183E  K176N   3  4  5  6 Emergence of relapse-specific PRPS1 mutations during remission, as detected by ultra-deep sequencing (mean, 250,000 reads). Key indicates sample ID of specific study individuals and their respective PRPS1 mutations. (c) Relapse-associated mutant PRPS1 residues mapped onto the crystal structure of the human PRPS1 dimer showing one subunit in beige and the other in green. Docked ATP (active site) and GDP (allosteric site) are shown as yellow and red stick models, respectively. Spheres, αC atoms of mutant residues; sticks, mutant residues. A and B in GDP_A and GDP_B represent the two allosteric sites of PRPS1. npg a r t i c l e s PRPS1 in response to 6-MP and 6-TG in the Reh human ALL cell line. Cell viability dramatically increased after treatment with both 6-MP (mean fold increase over vector control, 29; range, 12-54) and 6-TG (mean fold increase over vector control, 34; range, 28-41) in cells expressing 12 of the 17 respective mutants (S103T, S103N, S103I, N114D, N144S, G174E, K176N, D183E, A190T, A190V, L191F and T303S) ( Fig. 2a and Supplementary Figs. 4 and 5) , whereas cells transfected with WT PRPS1 conferred slight resistance to 6-MP and 6-TG, consistent with a gain-of-function mechanism in drug resistance. Overall, these effects were similar to those of the previously characterized R238W relapse-specific mutation in NT5C2 (refs. 7,8) (Supplementary Fig. 6 ). Five PRPS1 mutants, V53A, D139G, I72V, C77S and Y311C, did not dramatically increase drug resistance ( Supplementary Fig. 7 ), were only found in single cases ( Fig. 1a) and did not structurally map to the clustered regions (Supplementary Fig. 8 ; D139G is located in a separate dimer interface), and therefore were not pursued further in this work.
We also characterized activating mutant D183H with the reducedfunction PRPS1 mutants M115T in Charcot-Marie-Tooth disease 5 (CMTX5) and A87T in deafness-2 (DFN2) (ref. 20) as controls in our viability assay. The D183H mutant conferred resistance similarly to drug-resistant mutants, whereas the reduced-function mutants and PRPS1 knockdown had little effect on drug resistance ( Fig. 2 and Supplementary Figs. 7 and 9). We observed similar results in the Jurkat human T-ALL cell line (Supplementary Fig. 10 ). Interestingly, these relapse-specific PRPS1 mutants had minimal effects on sensitivity to other chemotherapies that are used in ALL treatment, such as methotrexate, cytosine arabinoside, daunorubicin and l-asparaginase Table 2 Clinical characteristics of childhood B-ALL subjects with or without a PRPS1 mutation Characteristic Chinese cohort (n = 138)
German cohort (n = 220) ( Supplementary Fig. 11 ). Our results suggest that these PRPS1 mutants behave similarly to gain-of-function mutants and are resistant to a specific class of drugs used in ALL treatment, purine analogs, as opposed to having defects in pathways (for example, apoptosis) common to classes of cytotoxic agents. Thiopurines are believed to exert their cytotoxicity primarily by incorporating thioguanine into DNA; post-replicative mismatch repair of aberrant base pairs containing thioguanine then generates potentially lethal DNA lesions, leading to DNA damage response (DDR) and apoptosis 22 . We found that cells expressing drug-resistant PRPS1 mutants were significantly more resistant to apoptosis after thiopurine treatment than those expressing vector controls ( Fig. 2b , P < 0.05). In addition, the DDR biomarkers γ-H2AX and phospho-CHK2 (T68) and the apoptosis biomarker cleaved poly (ADP-ribose) polymerase (PARP) were observed at lower levels in cells with drugresistant PRPS1 mutants than in those with WT PRPS1 or negative controls ( Fig. 2c and Supplementary Fig. 12 ), consistent with reduced DNA damage.
To provide insight into how PRPS1 mutants influence thiopurineinduced DNA damage, we examined the effects of the PRPS1 mutations on thiopurine prodrug conversion (Fig. 2d) . After treatment with 6-MP, Reh cells expressing drug-resistant PRPS1 mutants contained dramatically less thioinosine monophosphate (TIMP, the initial 6-MP conversion product), downstream metabolite thioguanine monophosphate (TGMP), and their derivatives than did controls (Fig. 2d-f and Supplementary Figs. 13 and 14) . PRPS1 produces phosphoribosyl pyrophosphate (PRPP), which is used by the salvage enzyme HPRT1 to convert 6-MP into TIMP (Fig. 2d) ; the observed inhibition of TIMP production by PRPS1 mutants could involve either PRPP reduction through a loss-of-function mechanism or inhibition of TIMP production independent of PRPP.
Activating PRPS1 mutants reduce nucleotide feedback inhibition As PRPS1 activity was best characterized in cellular assays 23 , we measured the activity of different PRPS1 mutants in Reh cells by following the generation of [ 13 C 5 ]-PRPP from [ 13 C 6 ]-glucose through the pentose phosphate pathway (Fig. 3a,b) . All 12 drug-resistant PRPS1 mutants increased production of PRPP (fold increase over vector control, 3-8) (Supplementary Fig. 15 ). Furthermore, drugresistant PRPS1 mutants caused a 4-12-fold increase in nucleotide IMP incorporation of [ 13 C 2 , 15 N]-glycine ( Supplementary  Fig. 16 ), suggesting activation of the de novo purine synthesis pathway. Results were similar when we measured the total IMP concentration and that of the IMP metabolite hypoxanthine (HX) in Reh cells (Supplementary Figs. 16 and 17) . In Reh cells expressing drugresistant PRPS1 mutants, we also noted an increase (although smaller than that in the de novo pathway) in purine salvage pathway activity, as shown by IMP incorporation of [ 13 C 5 , 15 N 4 ]-hypoxanthine (Fig. 3b,c) . Of all the nucleotides measured, HX concentrations most dramatically increased, from approximately 1 µM in cells expressing vector control to approximately 40-60 µM in cells expressing drugresistant PRPS1 mutants. Vector  WT  S103T  S103N  S103l  N144S  T303S  N114D  G174E  K176N  D183E  A190T  A190V  L191F  D183H  A87T WT  S103T  S103N  S103l  N144S  T303S  N114D  G174E  K176N  D183E  A190T  A190V  L191F  D183H  A87T 
Kinetic defects underlying PRPS1 superactivity include either regulatory defects (reduced feedback inhibition of purine biosynthesis) or catalytic defects (increased maximal velocity of catalysis) 15 . To study the mutations' effects on specific enzyme activities, we purified and assayed WT PRPS1, nine drug-resistant mutants, and two previously characterized reduced-function mutants ( Supplementary  Fig. 18 ), and found that none of the drug-resistant mutants had increased maximal velocity (Supplementary Table 9 ). We then measured nucleotide feedback inhibition of PRPS1 activity in an enzymatic activity assay with increasing quantities of ADP or GDP. All drug-resistant PRPS1 mutants showed dramatic shifts in ADP and GDP inhibition of PRPS1 activity (increase in IC 50 ) (Fig. 3d and  Supplementary Table 10) , implicating reduced feedback inhibition as the mechanism for the gain-of-function phenotype. Although the drug-resistant mutations consist of two structural groups (dimer interface versus allosteric site), they showed similar negative feedback defects, consistent with the previous observation that mutations in either protein-protein interfaces or nucleotide binding sites can affect allosteric enzyme regulation 24 . We often used A190T and S103T mutants as representatives of the two structural groups for our detailed mechanistic studies, as they were at the most frequently mutated sites on PRPS1 (62.5% of all cases) (Fig. 1a) .
PRPS1 feedback inhibition was better characterized in cell-based assays 23 . ADP or GDP addition reduced PRPS1 cellular activity by approximately 50%, as measured by metabolite flux in the control WT cells, but had no effect in cells expressing representative A190T or S103T mutants (Fig. 3e) , further supporting the hypothesis that PRPS1 mutants cause defects in the nucleotide feedback inhibition of their activities. Together, our results suggest that negative feedback-defective PRPS1 mutants allow cells to continue the biosynthesis of nucleotides even when their intracellular nucleotide concentrations are elevated.
Elevated HX inhibits HPRT1-mediated 6-MP conversion
The gain-of-function nature of PRPS1 drug-resistant mutants suggested two possible mechanisms of inhibiting TIMP production. One is that HPRT1 is feedback-inhibited by increased IMP 25 , which is not supported by the fact that cellular HPRT1 activity is not reduced in cells expressing PRPS1 mutants (Fig. 3b,c) . Alternatively, because 6-MP is an analog of the IMP catabolic metabolite HX, elevated HX could competitively inhibit 6-MP conversion, leading to reduced DNA damage. Both the purine synthesis end-product IMP and its metabolite HX can mediate drug resistance and thiopurine-conversion inhibition (Fig. 4a,b and Supplementary  Figs. 19-22) . Inside the cell, IMP slightly inhibited HPRT1-dependent salvage pathway activity but suppressed thiopurine conversion to a much greater extent, probably through its catabolic metabolite HX ( Supplementary  Fig. 23) . Consistent with the cellular data, increased IMP can only partially inhibit HPRT1 enzymatic activity at the relevant concentration (5-50 µM) with an IC 50 of 310 µM (Supplementary Fig. 24 ), whereas increased HX can effectively inhibit HPRT1-catalyzed 6-MP conversion at the relevant concentrations (1-100 µM) with an IC 50 of 7.7 µM in enzyme assays (Fig. 4c,d ). HX was preferred over 6-MP as a substrate for HPRT1 with a catalytic efficiency of 43.9-fold higher (HX has a 6-fold lower Michaelis constant (K m ) and a 7.2-fold higher maximal velocity (V m ) than 6-MP; V m /K m ratio, 43.9) (Fig. 4c,d) . These data suggest that HX competitive inhibition of 6-MP conversion instead of IMP feedback inhibition of HPRT1 activity is the main mechanism by which enhanced de novo purine biosynthesis causes thiopurine resistance.
Therapeutic strategy targeting de novo purine biosynthesis
To test whether enhanced de novo purine synthesis is necessary for the drug resistance phenotype, we knocked down de novo pathway-specific ATIC and GART by using CRISPR-Cas9 technology. ATIC or GART knockdown effectively reversed the 6-MP resistance phenotype and HX increase in Reh cells transfected with A190T and S103T PRPS1 mutants but had little effect in Reh cells transfected with vector alone or WT PRPS1 (Supplementary Fig. 25 ). Together 
npg a r t i c l e s
with the results discussed earlier, our data suggest that an enhanced de novo pathway is not only sufficient but also necessary for PRPS1 mutant-driven drug resistance. Small-molecule inhibitors of de novo purine biosynthesis have been tested as drugs against cancer 26 , and GART inhibitors are already in clinical development. Among them, lometrexol (also called DDATHF) exhibits antitumor activity (several partial responses and one complete response in phase 1 clinical trials) 27 . Lometrexol treatment of either PRPS1 A190T-or S103T-expressing cells inhibited de novo purine synthesis and reversed PRPS1 mutant-driven thiopurine drug resistance (Fig. 4e,f and Supplementary Fig. 26 ). This striking result suggests that pharmacological inhibition of GART may serve as a therapeutic strategy to overcome PRPS1 mutation-driven thiopurine resistance in relapsed ALL.
DISCUSSION
Two direct mechanisms of modulating thiopurine activity have been identified: methylation by TPMT 22 and clearance of cytotoxic nucleotides by relapse-specific NT5C2 mutants 7, 8 . Here we identified an indirect metabolic mechanism involving negative feedback-defective PRPS1 mutants and competitive inhibition of thiopurine activation in about 6.7% of relapsed childhood B-ALL cases (13.0% in the Chinese cohort, 2.7% in the German cohort). These distinguishing PRPS1 mutations are relapse specific and acquired during the latent phase of the disease during remission (as determined by ultra-deep sequencing at the resolution of 250,000 reads). All individuals with PRPS1 mutations relapsed early on-treatment, having an inferior prognosis 28 . We noticed that the PRPS1 mutant allele fraction increased drastically before clinical relapse, suggesting that clonal expansion occurs after the acquisition of a PRPS1 mutation (Fig. 1b) . De novo nucleotide biosynthesis is often upregulated in cancer cells 29 , as sufficient nucleotide pools are required to maintain DNA fidelity during replication 30 and to bypass oncogene-induced senescence 31 . Multiple levels of interaction between purine biosynthesis and DNA damage response have been discovered [32] [33] [34] , and PRPS1 mutations may have other roles in tumor relapse.
PRPS1 is feedback regulated by allosteric interaction, a key means of metabolic regulation in vivo by which pathway production is adjusted to the level of end-product use 24, 35 . To our knowledge, this is the first report of a deregulated metabolic feedback mechanism in cancer drug resistance, presenting an intriguing process that couples thiopurine resistance with de novo purine synthesis pathway activation to accommodate different needs of tumor cells during relapse. This biochemical gain-of-function mechanism is also supported by the genetic finding of mutations distal to PRPS1 in the de novo purine biosynthesis pathway (Fig. 4g) . These findings also suggest therapeutic strategies for overcoming such drug resistance in childhood ALL, as small-molecule inhibitors of de novo purine biosynthesis have already been developed against cancer 27 . The GART inhibitor lometrexol can sensitize tumor cells to thiopurines and overcome the drug resistance mechanism caused by PRPS1 activating mutations.
Tumor cells show abnormal nucleotide metabolism, as manifested by a larger nucleotide pool and a more active nucleotide anabolic pathway 29, 35 . Identifying the mechanism by which transformed cells achieve enhanced nucleotide biosynthesis may point to clinical anticancer strategies. It was shown recently that c-Myc (v-myc avian myelocytomatosis viral oncogene homolog)-driven translational upregulation of the otherwise weakly expressed PRPS2 can enhance nucleotide biosynthesis in Myc-transformed cells 36 . Here we demonstrated that negative feedback-defective PRPS1 mutants can also drive nucleotide biosynthesis, offering a new mechanism by which nucleotide pools are enlarged during tumor relapse. We believe that disruption of the purine feedback inhibition mechanism, as identified here in relapsed childhood ALL, could have broad implications for many additional cancer types, thus warranting renewed interest in targeting the de novo purine synthesis pathway for the treatment of human cancers.
METHODS
Methods and any associated references are available in the online version of the paper. Table 7b ). All patients of the German cohort presented with a first isolated bone marrow relapse or a first combined bone marrow/extramedullary relapse of precursor B-ALL. Bone marrow and peripheral blood samples were obtained at the time of relapse, between January 2002 and July 2012. Genomic DNA was extracted from bone marrow leukemic cells after leukemia cell recovery (for whole-exome sequencing) or shaving of bone marrow slides (for the validation study in part of the Chinese cohort) by using QIAamp DNA blood mini kit (Qiagen) or NucleoSpin Tissue kit (Macherey-Nagel, Germany). The Chinese study was approved and supervised by the SCMC Ethics Committee, which serves the function of an institutional review board ensuring human subject protections; the clinical trial number of the SCMC-ALL-2005 protocol is ChiCTR-ONC-14005003 (Chinese Clinical Trial Registry). Use of the samples from the German multi-center randomized phase 3 trial ALL-REZ BFM 2002 (NCT00114348, ClinicalTrials.gov) was approved by the Medical Faculty Ethics Committee of the Humboldt University Berlin, Germany. Written informed consent was obtained from patients or their guardians in both centers.
Whole-exome sequencing and analysis. Whole-exome capture libraries were prepared using the SureSelect Human All Exon 50 Mb or 38 Mb kit (Agilent Technologies). We performed paired-end (2 × 100 bp) sequencing by using the Illumina HiSeq 2000 instrument, imaging analysis and base calls by using the Illumina Real Time Analysis (RTA) Pipeline software, version 1.9. After removing reads whose sequence matched the sequencing adapters and lowquality reads (in which more than 50% of bases had a Phred quality score <5), the remaining reads were aligned to the reference human genome (hg19, http://genome.ucsc.edu/) using Burrows-Wheeler analysis with default parameters. We identified sites that differed from the reference independently in each sample. SNVs/indels were detected as previously described 37, 38 . The reference human genome assembly GRCh37-lite was used to map all samples. SNVs were identified using GATK (https://www.broadinstitute.org/gatk/) and filtered using the recommended threshold (SNV Phred quality score ≥20, more than three reads covered, depth ≥ 8×). After removing germline variants known to have a mutation rate ≥ 5% in normal bone marrow samples, the remainders were potential somatic variants in all diagnosis and relapse samples. We used the Affymetrix Genome-Wide Human SNP 6.0 Array to compare sequencing reads with genotypes and found a high concordance (>97% in all cases except one) (Supplementary Table 4) . The translocation data were identified by RT-PCR and a customer-ordered target-sequencing panel followed by verification with Sanger sequencing. Predicted protein function changes caused by amino acid substitutions in Supplementary Table 2 were examined using PolyPhen (http://genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/).
Validation and recurrence of PRPS1 mutations. We resequenced all exons of PRPS1 in an independent Chinese cohort of 144 relapse cases. On the basis of preliminary data from this cohort, we analyzed PRPS1 hot-spot mutations in all exons in the German cohort by targeted Sanger sequencing. PCR amplification used TaKaRa Ex Taq DNA polymerase (Hot start version) with DNA-specific primers (Supplementary Table 11) . Genomic re-sequencing was performed on an ABI 3730xL Genetic Analyzer according to the manufacturer's protocol, and the resulting data were screened for mutations by automated and manual methods. We sequenced the related pathway genes, including PRPS2, PPAT, ATIC, GART, PAICS and PFAS (de novo purine biosynthesis); TPMT and NT5C2 (thiopurine metabolism); and HPRT1 (purine salvage pathway).
Cell culture. The Reh and Jurkat leukemia cell lines were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin G and 100 µg/ml streptomycin. HEK-293T cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin G and 100 µg/ml streptomycin. All cells were incubated at 37 °C in 5% CO 2 unless otherwise specified.
Lentivirus production and infection. The human PRPS1 coding region was cloned into pGV303 GFP vector (Shanghai GeneChem), and different mutations were constructed by site-directed mutagenesis and confirmed by DNA sequencing. The lentiviral constructs were packaged in plasmids PSPAX 2 and PMD 2 G, and transfected into HEK-293T cells using the calcium phosphate method to produce replication-defective virus. Supernatant was harvested after 48 h, concentrated in a 100-kD column (Amicon purification system, Millipore), and transfected into Reh cells (in which WT PRPS1 sequence was verified) supplemented with 8 µg/ml Polybrene (Sigma). The medium was changed 24 h after infection, and GFP-positive cells were sorted in a Moflo XDP (Beckman Coulter).
Cell viability and apoptosis. Cell viability was determined by using the CellTiterGlo Luminescent kit (Promega) according to the manufacturer's instructions. Cells were seeded in 96-well plates (10,000 cells per well) and treated for 72 h with serially diluted drugs. CellTiter-Glo reagents (50 µl) was added to each well and mixed for 10 min before the luminescence was measured on a microplate reader (Biotek, USA). Apoptosis was measured by staining with annexin V-phycoerythrin (PE) and 7-aminoactinomycin D (7-AAD) (AnnexinV-PE Apoptosis Detection kit, BD Pharmingen) followed by flow cytometry on a FACS flow cytometer (BD, Canto II). All experiments were performed in triplicate, and results were calculated as the mean ± s.d.
Western blot analysis. Treated cells were harvested in lysis buffer and analyzed by SDS-PAGE with the following antibodies: γ-H2AX (S139) (cat. 9718; 1:1,000 dilution, Cell Signaling Technology (CST), USA), H2AX (cat. 7631; 1:1,000 dilution, CST, USA), phospho-CHK2 (T68) (cat. 1538-1; 1:1,000 dilution, CST, USA), CHK2 (cat. 3428-1; 1:50,000 dilution, Epitomics, USA), PARP (cat. 9542; 1:1,000 dilution, CST, USA), cleaved PARP (cat. 5625; 1:1,000 dilution, CST, USA), Histag (cat. sc-8036; 1:1,000 dilution, Santa Cruz Biotechnology, USA), and actin (cat. sc-8432, 1:5,000 dilution, Santa Cruz Biotechnology, USA). Immunoblots were analyzed using the Odyssey system (LI-COR Biosciences, USA).
Protein purification. We cloned WT and mutated PRPS1 and HPRT1 genes with an N-terminal hexahistidine (6 His) tag into the pET-28a expression vector. The Escherichia coli BL21 (DE3) strain (Tiangen) was transfected with the plasmids for overexpression. The harvested cell pellets were suspended in buffer A (50 mM NaH 2 PO 4 (pH 8.0), 1 M NaCl, 15% (wt/vol) glycerol, 5 mM 2-mercaptoethanol and 1 mM PMSF) and lysed on ice by sonication disruption. The supernatants were collected by centrifugation and loaded on a pre-balanced 2-ml Ni-Sepharose FF column (GE Healthcare) in the AKTA purifier system. The column was washed with buffer A and eluted with buffer B (buffer A + 500 mM imidazole). We removed imidazole by buffer exchange in G25 desalting columns (GE Healthcare), and assessed protein expression and purity by SDS-PAGE with Coomassie blue staining.
Enzymatic activity. ADP and GDP feedback inhibition of PRPS1 were assayed using the Kinase-Glo Kit (Promega) according to the manufacturer's instructions. ADP or GDP was diluted with assay buffer (50 mM Tris, pH 7.5, 10 mM MgCl 2 , 1 mM DTT) from 5 mM to 0.25 µM. 10 µl enzyme mixture (500 µM ATP, 500 µM PRPP, 2 mM phosphate and 1-5 µg/ml PRPS1) was incubated at 37 °C for 1 h. The reaction was terminated by adding 10 µl kinaseGlo reagent. For the PRPS1 kinetics study, the quantity of AMP produced was measured indirectly by monitoring the decrease in absorbance of NADH at 340 nm by the enzyme coupling assay, as previously described 39 .
HPRT1 activity was assayed in a 60 µl mixture containing 200 µM PRPP plus various concentrations of HX or 6-MP. After addition of 2 nM HPRT1 and incubation at 37 °C for 10 min, the reaction was quenched by adding 180 µl of cold 80% methanol. Concentration of reaction products IMP and TIMP was measured by LC-MS (ABI 5500 Qtrap coupled with Waters Acquity UPLC). 
